The cytoprotective property of ethoxidol in patients with coronary heart disease

Abstract

Introduction: The widespread prevalence and high mortality rate from coronary heart disease (CHD), despite the accepted treatment standards, aim at finding the most rational drug combinations, expanding the range of drugs, and developing personalized approaches to their use.

Research tasks: determination of the cytoprotective properties of the antioxidant drug ethoxidol in patients with CHD.

Material and Methods: We examined 30 patients with CHD: stable angina pectoris of I-III functional classes. To determine the cytoprotective properties of ethoxidol, blood leukocytes of patients were studied in vitro by fluorescence microscopy using an Eclipse Ti-U inverted fluorescence microscope (Nikon, Japan). By staining leukocytes with fluorescent dyes (MitoTracker ™ Red CMXRos, Calcein AM, Ethidium bromide), living and dead cells were determined, mitochondrial fluorescence, and the cell viability index (VI_cells) was calculated. The materials were processed statistically.

Results: with the introduction of ethoxidol into a sample with a leukocyte suspension, a significant increase in VI_cells by 21% (from 41% to 62%, p <0.001) was observed, which indicates the presence of a cytoprotective property in this drug. A more detailed analysis of the dynamics of the VI_cells index showed two variants of changes in cell viability: in 80% of patients VI_cells was increased, on average, by 28% (from 36% to 64%, p <0.001) and in 20% of patients VI _cells was decreased, on average, by 10% (from 68% to 58%, p <0.05). The groups significantly differed in the initial level of cell viability (36% versus 68%, p <0.01), and in the initial level of mitochondrial fluorescence intensity: in the group of increasing cell viability under the influence of ethoxidol, the initial value of mitochondrial fluorescence was significantly lower (114.17 ± 3.63 relative units) in comparison with a group of decreased viability (144.14 ± 10.81 relative units, p<0.01). The value of mitochondrial fluorescence changed in both cases upward, but without achieving the reliability of differences.

Conclusion: the antioxidant drug ethoxidol has cytoprotective properties in patients with CHD. At the same time, there is some variability in changes in the viability of blood cells of patients under the influence of ethoxidol in the form of an increase (in 80% of cases) or a decrease (in 20% of cases) of this indicator, which indicates the need to develop a personalized approach to prescribing this drug to patients with CHD.